MYO3B-AS1

Across TCGA pan-cancer cohorts, MYO3B-AS1 RNA is linked to patient survival in 19 of 34 cancer types, making it the most broadly survival-associated MYO3B-AS1 data layer.

The strongest signal is observed in thyroid carcinoma (THCA), where higher MYO3B-AS1 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated MYO3B-AS1 expression acts as an unfavorable survival marker, although some lineages such as BRCA and LUAD show a favorable association.

THCA, KIRC, and LIHC are the cancer types where MYO3B-AS1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THCA	DFS	Tertile	All	0.699	0.894	.001	63	view →
KIRC	DFS	Tertile	III,IV	0.319	0.521	.002	32	view →
LIHC	OS	Tertile	All	0.286	0.602	.001	27	view →
CESC	DFS	Tertile	III,IV	0.457	0.833	.001	26	view →
ACC	OS	Tertile	All	0.677	0.917	.003	24	view →
BRCA	DFS	Tertile	III,IV	0.942	0.853	.002	21	view →
THYM	DFS	Tertile	All	0.734	0.957	.001	18	view →
MESO	OS	Quartile	II,III,IV	0.239	0.627	.008	18	view →
LUAD	DFS	Median	IV	0.643	0.350	.018	14	view →
UCS	DFS	Tertile	III,IV	0.576	0.187	.029	12	view →
UCEC	OS	Quartile	III,IV	0.739	0.839	.022	12	view →
SKCM	DFS	Median	All	0.266	0.164	.009	9	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 19 lineages.

MYO3B-AS1–THCA (DFS)

Open the THCA breakdown →